Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitors
Biotech
ESMO: Exelixis' TKI reduces risk of death by 20%
The company believes the data for zanzalintinib validate its hopes of having another “franchise molecule” on its hands.
James Waldron
Oct 20, 2025 2:30am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
Exelixis beats Bayer drug in cancer trial, sending stock higher
Jun 23, 2025 7:30am
Alumis hits stride as TYK2 inhibitor improves psoriasis in ph. 2
Mar 9, 2024 12:00pm
Blueprint drops lung cancer programs after seeing early data
Jan 9, 2024 9:22am
Safety signal sinks Theseus' cancer program—and its share price
Jul 14, 2023 7:20am
